Click to copy
Run the pack on this sample before you use real data. Run units 04 to 09 on both loans (unit 10 on the table you produce). Compare your result to the answer key. If one figure does not match, stop and find out why before you touch real data. One document is missing on purpose, so you see the pack stop on that figure and carry on with the rest. All names are fictional. Amounts are in millions. Test date 30 September 2026, last twelve months (LTM).
THESIS for this sample: "I expect Brightwater to be the tight one. Northgate should be fine." CLOSE_THRESHOLD 10 percent. Sign-off: the credit committee chair.
LOAN A: NORTHGATE PACKAGING
A1 Credit Agreement extract.
Page 4. Consolidated EBITDA means net income plus, without duplication, interest expense, income taxes, depreciation and amortization, and non cash charges including share based pay (that sum is Pre Add Back EBITDA), plus (e) restructuring costs, up to 15 percent of Pre Add Back EBITDA, plus (f) run rate cost savings from actions taken in the period and realized within 12 months, up to 10 percent of Pre Add Back EBITDA. Net Debt means Funded Debt (term loan, drawn revolver, finance leases) less Unrestricted Cash, with Unrestricted Cash netted up to 10.0. Fixed Charges means cash interest plus scheduled principal payments. Fixed Charge Coverage Ratio means (Consolidated EBITDA less unfinanced capital expenditure less cash taxes) divided by Fixed Charges.
Page 9. Section 7.11. Total Net Leverage Ratio (Net Debt over Consolidated EBITDA, LTM) shall not exceed 5.50 to 1.00 for test dates through 30 June 2026 and 5.25 to 1.00 for each test date after that. Fixed Charge Coverage Ratio shall not be less than 1.10 to 1.00.
A2 Compliance Certificate, quarter ended 30 September 2026, page 1. Adjusted EBITDA 42.0. Net Debt 192.0 (Funded Debt 202.0 less cash 10.0). Total Net Leverage 4.57x, required 5.25x. Fixed Charge Coverage 1.83x, required 1.10x. Page 2: "Changes since the prior certificate: none." Signed by the CFO.
A3 Financial statements.
Page 1, LTM to 30 September 2026: net income 8.0. Interest expense 14.0, of which cash interest 13.2. Income taxes 3.0, of which cash taxes paid 2.6. Depreciation and amortization 9.0. Share based pay 1.0. Restructuring charges (plant closure) 4.0. Capital expenditure 7.0, all paid from operating cash. Scheduled principal paid 4.5.
Page 2, 30 September 2026: term loan 175.0 (30 September 2025: 179.5). Revolver drawn 21.0. Finance leases 6.0. Cash 22.0, all unrestricted.
Page 3, management memo: the plant closure was completed in the period and delivers 3.0 of annual run rate savings, all realized within 12 months.
A4 The Q2 2026 compliance certificate: NOT IN THE FOLDER.
LOAN B: BRIGHTWATER DENTAL PARTNERS
B1 Credit Agreement extract.
Page 4. Same Consolidated EBITDA, Pre Add Back EBITDA, Net Debt (cash netted up to 10.0), Fixed Charges and Fixed Charge Coverage definitions as A1, except clauses (e) and (f) read: (e) restructuring and integration costs and (f) run rate synergies from Permitted Acquisitions, together not exceeding 15 percent of Pre Add Back EBITDA, calculated before giving effect to clauses (e) and (f).
Page 9. Section 7.11 as originally signed: Total Net Leverage Ratio shall not exceed 5.00 to 1.00. Fixed Charge Coverage Ratio shall not be less than 1.15 to 1.00. Section 7.12: the Sponsor may cure a breach by an equity contribution, up to two cures in any four quarters. The Cure Amount counts as Consolidated EBITDA for that test date.
B2 Amendment No. 1, dated 14 May 2026, page 2. Section 7.11 is replaced: Total Net Leverage Ratio shall not exceed 5.50 to 1.00 for each test date through 31 December 2026 and 5.25 to 1.00 after that. All other terms unchanged.
B3 Compliance Certificate, quarter ended 30 September 2026, page 1. Adjusted EBITDA 40.0. Net Debt 204.0 (Funded Debt 218.0 less cash 14.0). Total Net Leverage 5.10x, required 5.50x. Fixed Charge Coverage 1.57x, required 1.15x. No cure used. Signed by the CFO.
B4 Financial statements.
Page 1, LTM to 30 September 2026: net income 5.0. Interest expense 16.0, of which cash interest 15.5. Income taxes 2.0, of which cash taxes paid 1.8. Depreciation and amortization 8.0, including 1.4 of amortization of acquired intangibles. Share based pay 1.0. Restructuring and integration costs 3.5. Run rate synergies from the Hartwell clinics, a Permitted Acquisition closed on 3 February 2026: 4.5. Capital expenditure 6.0, unfinanced. Scheduled principal paid 5.0.
Page 2, 30 September 2026: term loan 200.0 (30 September 2025: 205.0). Revolver drawn 15.0. Finance leases 3.0. Cash 14.0, all unrestricted.
ANSWER KEY
LOAN A (pass direction)
Pre Add Back EBITDA 8.0 + 14.0 + 3.0 + 9.0 + 1.0 = 35.0. Restructuring 4.0 is under its cap 5.25 (15 percent of 35.0): PERMITTED. Run rate savings 3.0 is under its cap 3.5 (10 percent of 35.0): PERMITTED. Consolidated EBITDA 42.0, ties to A2 (gap 0.0).
Funded Debt 175.0 + 21.0 + 6.0 = 202.0. Cash 22.0 netted only up to 10.0. Net Debt 192.0 (trap answer: netting all 22.0 gives 180.0 and 4.29x).
Leverage 192.0 / 42.0 = 4.57x. Required 5.25x, because 30 September 2026 is after the 30 June 2026 step down date. Cushion 1 minus 4.571 over 5.25 = 12.9 percent.
Fixed Charge Coverage: (42.0 minus 7.0 minus 2.6) / (13.2 + 4.5) = 32.4 / 17.7 = 1.83x. Minimum 1.10x. Cushion 1 minus 1.10 over 1.83 = 39.9 percent.
Status FINE. Gap to the certificate: none. Nothing CHANGES THE DECISION and nothing is WORTH A QUESTION.
Checked, normal (EXPLAINED BY CONTEXT, all five): cash netted at 10.0 against 22.0 on the balance sheet, because the agreement caps it; required level 5.25x against 5.50x earlier, a step down; restructuring and run rate add backs large but inside the definition and the caps; term loan down 4.5, scheduled amortization; interest expense 14.0 against cash interest 13.2, non cash amortization.
Missing document: the Q2 2026 certificate. Headroom trend against last quarter is OPEN. Everything else above still runs.
LOAN B (breach direction)
Pre Add Back EBITDA 5.0 + 16.0 + 2.0 + 8.0 + 1.0 = 32.0. Claimed (e) plus (f) 3.5 + 4.5 = 8.0. Cap 15 percent of 32.0 = 4.8. Permitted 4.8, excess 3.2. Consolidated EBITDA 36.8, against 40.0 on the certificate (gap 3.2). Trap answer: a cap taken on the adjusted 40.0 gives 6.0, EBITDA 38.0 and 5.47x, which looks like a pass.
Funded Debt 200.0 + 15.0 + 3.0 = 218.0. Cash netted up to 10.0. Net Debt 208.0, against 204.0 on the certificate (gap 4.0).
Leverage 208.0 / 36.8 = 5.65x. Required 5.50x (Amendment No. 1, page 2, which replaced the original 5.00x for test dates through 31 December 2026). Cushion 1 minus 5.652 over 5.50 = minus 2.8 percent. BREACH, CHANGES THE DECISION.
Cure on the agreement's terms: EBITDA needed 208.0 / 5.50 = 37.82, so a Cure Amount of 1.02. Section 7.12 allows up to two in four quarters and none is used on B3, so a cure is open. This is a condition, not a reason to soften the status.
Fixed Charge Coverage: (36.8 minus 6.0 minus 1.8) / (15.5 + 5.0) = 29.0 / 20.5 = 1.41x. Minimum 1.15x. Cushion 18.7 percent. FINE.
The certificate shows compliance at 5.10x while the recompute on the agreement's own definitions shows 5.65x: the certificate overstates EBITDA by 3.2 and nets 4.0 too much cash. CHANGES THE DECISION, severity HIGH. Only the borrower's corrected certificate or a waiver closes it. Default if nothing is done: Brightwater stays at the top of the table as BREACH and nothing is sent.
Checked, normal (EXPLAINED BY CONTEXT): interest expense 16.0 against cash interest 15.5; D&A includes 1.4 of acquired intangible amortization; run rate synergies from a Permitted Acquisition are a permitted category and only the cap bites; term loan down 5.0, scheduled amortization; Amendment No. 1 is in the folder, so 5.50x is the right level.
Thesis check: the THESIS said Brightwater is the tight one. Confirmed, and tighter than the certificate shows. Northgate is fine.
Table order: Brightwater (minus 2.8 percent) first, Northgate (12.9 percent) second.
A run that flags a normal item, takes the trap answer, or guesses the missing document has failed.